The content on this site is intended for healthcare professionals only
ASCO 2021: Latest on PARPi and other treatments for mCRPC
Dr Neal Shore and Prof Oliver Sartor
4 Jun 2021
mCRPC: Latest developments in diagnostics and combination therapies
Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor
4 Jun 2021
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally ad...
Dr Terence Friedlander - UCSF, San Francisco, USA
4 Jun 2021
ASCO 2021: Renal cancer roundup
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
4 Jun 2021
KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy f...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
4 Jun 2021
OncoAlert and ecancer weekly roundup for April 26 - May 3, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
7 May 2021
Healthy lifestyle may offset risk of lethal prostate cancer in men with high gen...
Dr Anna Plym - Harvard University, Boston, USA
15 Apr 2021
OncoAlert and ecancer weekly roundup for March 01 - 06, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
8 Mar 2021
Promise of personalised medicine for patients with prostate cancer
Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt ...
26 Feb 2021
Cabozantinib most effective treatment for metastatic papillary kidney cancer
Dr Sumanta Pal - City of Hope, Duarte, USA
26 Feb 2021
Oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell c...
Dr Todd Michael Bauer - Sarah Cannon Research Institute and Tennessee Oncology, ...
26 Feb 2021
SEMS trial: result of a prospective, multi-institutional phase II clinical trial...
Dr Sia Daneshmand - University of Southern California, Los Angeles, USA
24 Feb 2021
